KR102493543B1 - 자가면역 질환의 치료를 위한 조절 t 세포를 선택적으로 활성화시키는 분자 - Google Patents

자가면역 질환의 치료를 위한 조절 t 세포를 선택적으로 활성화시키는 분자 Download PDF

Info

Publication number
KR102493543B1
KR102493543B1 KR1020177001922A KR20177001922A KR102493543B1 KR 102493543 B1 KR102493543 B1 KR 102493543B1 KR 1020177001922 A KR1020177001922 A KR 1020177001922A KR 20177001922 A KR20177001922 A KR 20177001922A KR 102493543 B1 KR102493543 B1 KR 102493543B1
Authority
KR
South Korea
Prior art keywords
leu
lys
ser
val
thr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020177001922A
Other languages
English (en)
Korean (ko)
Other versions
KR20170028938A (ko
Inventor
제프리 그레베
Original Assignee
데리니아, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55163946&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR102493543(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 데리니아, 인크. filed Critical 데리니아, 인크.
Publication of KR20170028938A publication Critical patent/KR20170028938A/ko
Application granted granted Critical
Publication of KR102493543B1 publication Critical patent/KR102493543B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
KR1020177001922A 2014-07-21 2015-07-20 자가면역 질환의 치료를 위한 조절 t 세포를 선택적으로 활성화시키는 분자 Active KR102493543B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461999241P 2014-07-21 2014-07-21
US61/999,241 2014-07-21
PCT/US2015/041177 WO2016014428A2 (en) 2014-07-21 2015-07-20 Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases

Publications (2)

Publication Number Publication Date
KR20170028938A KR20170028938A (ko) 2017-03-14
KR102493543B1 true KR102493543B1 (ko) 2023-01-30

Family

ID=55163946

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020177001922A Active KR102493543B1 (ko) 2014-07-21 2015-07-20 자가면역 질환의 치료를 위한 조절 t 세포를 선택적으로 활성화시키는 분자

Country Status (22)

Country Link
US (6) US20170051029A1 (enExample)
EP (2) EP3172227B9 (enExample)
JP (2) JP6768633B2 (enExample)
KR (1) KR102493543B1 (enExample)
CN (2) CN114133456A (enExample)
AU (3) AU2015292889C1 (enExample)
CA (1) CA2954847A1 (enExample)
DK (1) DK3172227T3 (enExample)
EA (2) EA202190903A3 (enExample)
ES (1) ES2763198T3 (enExample)
GB (1) GB2538666A (enExample)
HU (1) HUE046065T2 (enExample)
IL (3) IL289475B2 (enExample)
LT (1) LT3172227T (enExample)
MX (2) MX378790B (enExample)
PL (1) PL3172227T3 (enExample)
PT (1) PT3172227T (enExample)
RS (1) RS59789B1 (enExample)
SG (2) SG11201700514SA (enExample)
SI (1) SI3172227T1 (enExample)
WO (1) WO2016014428A2 (enExample)
ZA (1) ZA201700344B (enExample)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112015013557B1 (pt) 2012-12-11 2021-12-14 Albert Einstein College Of Medicine Sistema, método, método para determinar o efeito de um resíduo de aminoácido predeterminado de uma primeira proteína sobre a ligação da primeira proteína a uma segunda proteína e polipeptídeo pd-l1 mutante
KR102493543B1 (ko) * 2014-07-21 2023-01-30 데리니아, 인크. 자가면역 질환의 치료를 위한 조절 t 세포를 선택적으로 활성화시키는 분자
PL3482766T3 (pl) 2014-08-11 2020-11-16 Delinia, Inc. Modyfikowane warianty il-2, które selektywnie aktywują limfocyty t regulatorowe do leczenia chorób autoimmunologicznych
MX2017012966A (es) 2015-04-10 2018-06-06 Amgen Inc Muteinas de interleuquina 2 para la expansion de celulas t regulatorias.
US20170204154A1 (en) 2016-01-20 2017-07-20 Delinia, Inc. Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases
KR20250133490A (ko) * 2016-05-04 2025-09-05 암젠 인크 T-조절 세포의 증식을 위한 인터류킨-2 뮤테인
CN109689096A (zh) 2016-05-18 2019-04-26 阿尔伯特爱因斯坦医学院公司 变体pd-l1多肽、t细胞调节性多聚体多肽及其使用方法
KR20190019068A (ko) 2016-05-18 2019-02-26 큐 바이오파마, 인크. T-세포 조절 다량체 폴리펩타이드 및 이의 사용 방법
EA201991142A1 (ru) * 2016-11-08 2019-10-31 Варианты il-2 для лечения аутоиммунных заболеваний
EP3554525A4 (en) 2016-12-13 2020-08-19 Delinia, Inc. MULTIVALENT REGULATORS T LYMPHOCYTE MODULATORS
PT3558339T (pt) 2016-12-22 2024-03-15 Cue Biopharma Inc Polipeptídeos multiméricos moduladores de células t e métodos de utilização dos mesmos
US11851471B2 (en) 2017-01-09 2023-12-26 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
CA3056630A1 (en) 2017-03-15 2018-09-20 Pandion Therapeutics, Inc. Targeted immunotolerance
CA3054955A1 (en) 2017-03-15 2018-09-20 Cue Biopharma, Inc. Methods for modulating an immune response
WO2018181638A1 (ja) * 2017-03-29 2018-10-04 国立大学法人宮崎大学 長時間作用型アドレノメデュリン誘導体
JP2020521452A (ja) 2017-05-24 2020-07-27 パンディオン・セラピューティクス・インコーポレイテッド 標的化免疫寛容
EP3713592A4 (en) 2017-11-21 2022-01-12 The Board of Trustees of the Leland Stanford Junior University INTERLEUKIN-2 PARTIAL AGONISTS
WO2019112854A1 (en) * 2017-12-06 2019-06-13 Pandion Therapeutics, Inc. Il-2 muteins and uses thereof
US10174091B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
USRE50550E1 (en) 2017-12-06 2025-08-26 Pandion Operations, Inc. IL-2 muteins and uses thereof
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
MA51291A (fr) 2017-12-19 2020-10-28 Xencor Inc Protéines de fusion il-2 fc modifiées
WO2019131964A1 (ja) 2017-12-27 2019-07-04 協和発酵キリン株式会社 Ｉｌ－２改変体
EP3737689A4 (en) 2018-01-09 2021-12-01 Cue Biopharma, Inc. MULTIMER POLYPEPTIDES T-LYMPHOCYTE MODULATORS AND THEIR METHODS OF USE
CN112105632A (zh) 2018-01-24 2020-12-18 北京智康博药肿瘤医学研究有限公司 细胞因子融合蛋白
WO2019144309A1 (en) * 2018-01-24 2019-08-01 Beijing Percans Oncology Co. Ltd. Cytokine Fusion Proteins
WO2019158764A1 (en) 2018-02-16 2019-08-22 Iltoo Pharma Use of interleukin 2 for treating sjögren's syndrome
US11359000B2 (en) 2018-03-28 2022-06-14 Bristol-Myers Squibb Company Interleukin-2/Interleukin-2 receptor alpha fusion proteins and methods of use
EP3552738B1 (en) * 2018-04-12 2024-07-31 Sandvik Machining Solutions AB A method of producing an additive manufactured object
CN112638406B (zh) 2018-06-22 2025-04-22 科优基因公司 白介素-2变体及其使用方法
WO2020007937A1 (en) 2018-07-03 2020-01-09 Iltoo Pharma Use of interleukin-2 for treating systemic sclerosis
US12459980B2 (en) 2018-07-25 2025-11-04 AskGene Pharma, Inc. IL-21 prodrugs and methods of use thereof
AU2019317353B2 (en) 2018-08-06 2022-02-17 Medikine, Inc. IL-2 receptor binding compounds
WO2020035482A1 (en) 2018-08-13 2020-02-20 Iltoo Pharma Combination of interleukin-2 with an interleukin 1 inhibitor, conjugates and therapeutic uses thereof
KR20210107714A (ko) * 2018-12-21 2021-09-01 지앙수 헨그루이 메디슨 컴퍼니 리미티드 인간 인터류킨-2 변이체 또는 이의 유도체
SG11202107272SA (en) 2019-02-01 2021-07-29 Regeneron Pharma Anti-il2 receptor gamma antigen-binding proteins
KR20210128443A (ko) 2019-02-15 2021-10-26 인테그럴 몰큘러 인코포레이티드 클라우딘 6 항체 및 이의 용도
CA3129317A1 (en) 2019-02-15 2020-08-20 Integral Molecular, Inc. Antibodies comprising a common light chain and uses thereof
CA3141327A1 (en) 2019-05-20 2020-11-26 Pandion Operations, Inc. Madcam targeted immunotolerance
AU2020291012B2 (en) 2019-06-12 2025-09-25 AskGene Pharma, Inc. Novel IL-15 prodrugs and methods of use thereof
KR20220051177A (ko) 2019-07-26 2022-04-26 비스테라, 인크. 인터류킨-2 작용제 및 이의 용도
US20220306714A1 (en) * 2019-08-12 2022-09-29 AskGene Pharma, Inc. Il-2 fusion proteins that preferentially bind il-2ralpha
CA3160466A1 (en) 2019-11-05 2021-05-14 Medikine, Inc. Dual il-2r and il-7r binding compounds
CN115087664A (zh) 2019-11-05 2022-09-20 麦地金公司 IL-2Rβγc结合化合物
CN115190885A (zh) * 2019-12-12 2022-10-14 艾尔图制药公司 白细胞介素2嵌合构建体
WO2021127495A1 (en) * 2019-12-20 2021-06-24 Regeneron Pharmaceuticals, Inc. Novel il2 agonists and methods of use thereof
CN115362168A (zh) 2020-01-14 2022-11-18 辛德凯因股份有限公司 偏向化il2突变蛋白方法和组合物
CN115297886A (zh) 2020-02-03 2022-11-04 麦地金公司 IL-7Rα结合化合物
WO2021158623A1 (en) 2020-02-03 2021-08-12 Medikine, Inc. IL-7Rαγc BINDING COMPOUNDS
WO2021168079A1 (en) 2020-02-21 2021-08-26 Pandion Operations, Inc. Tissue targeted immunotolerance with a cd39 effector
US11028132B1 (en) 2020-04-07 2021-06-08 Yitzhak Rosen Half-life optimized linker composition
WO2021231376A2 (en) 2020-05-12 2021-11-18 Cue Biopharma, Inc. Multimeric t-cell modulatory polypeptides and methods of use thereof
IL298136A (en) 2020-05-13 2023-01-01 Bonum Therapeutics Inc Preparations of protein complexes and methods of using them
EP4208474A2 (en) * 2020-09-01 2023-07-12 Takeda Pharmaceutical Company Limited Interleukin-2 muteins and uses thereof
JP2023541366A (ja) 2020-09-09 2023-10-02 キュー バイオファーマ， インコーポレイテッド １型真性糖尿病（ｔ１ｄ）を治療するためのｍｈｃクラスｉｉ ｔ細胞調節多量体ポリペプチド及びその使用方法
MX2023004598A (es) 2020-10-23 2023-06-29 Asher Biotherapeutics Inc Fusiones con moléculas de unión al antígeno cd8 para modular la función de las células inmunitarias.
MX2023005030A (es) 2020-10-29 2023-05-16 Bristol Myers Squibb Co Proteinas de fusion para el tratamiento de enfermedades.
CA3201446A1 (en) 2020-11-13 2022-05-19 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Pharmaceutical composition comprising human interleukin 2 variant or derivative thereof and use thereof
KR20230129018A (ko) 2020-12-04 2023-09-05 비스테라, 인크. 인터류킨-2 작용제를 사용하는 방법
IL304365B2 (en) * 2021-03-31 2025-04-01 Hanmi Pharmaceutical Co Ltd A novel conjugate of an IL2 immunostimulatory analog and method of preparation thereof
US20220323607A1 (en) 2021-04-09 2022-10-13 Selecta Biosciences, Inc. Synthetic nanocarriers comprising an immunosuppressant in combination with high affinity il-2 receptor agonists to enhance immune tolerance
MX2024004291A (es) 2021-10-06 2024-06-28 Iltoo Pharma Construcciones quiméricas de interleucina 2 con especificidad de direccionamiento a tejidos inflamados.
EP4463135A2 (en) 2022-01-10 2024-11-20 Sana Biotechnology, Inc. Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
WO2023133319A1 (en) 2022-01-10 2023-07-13 Selecta Biosciences, Inc. High affinity il-2 receptor agonists and synthetic nanocarrier dose sparing
US20230322884A1 (en) 2022-03-09 2023-10-12 Selecta Biosciences, Inc. Immunosuppressant in combination with high affinity il-2 receptor agonists and related dosing
US20230372535A1 (en) 2022-03-25 2023-11-23 Selecta Biosciences, Inc. Synthetic nanocarriers comprising an immunosuppressant in combination with high affinity il-2 receptor agonists and anti-igm agents
WO2023193015A1 (en) 2022-04-01 2023-10-05 Sana Biotechnology, Inc. Cytokine receptor agonist and viral vector combination therapies
US11999771B2 (en) 2022-04-07 2024-06-04 Medikine, Inc. IL-7Rαγc ligand immunoglobulin fusion proteins
US20230381277A1 (en) 2022-04-08 2023-11-30 Selecta Biosciences, Inc. High affinity il-2 receptor agonists and immunosuppressants to enhance immune tolerance
CN115322260A (zh) * 2022-06-13 2022-11-11 杭州高田生物医药有限公司 能够在肠道内富集且增殖调节性t细胞的融合蛋白及应用
WO2024056154A1 (en) 2022-09-12 2024-03-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Interleukin-2 for use in treating autism spectrum disorder
CN120282987A (zh) 2022-11-30 2025-07-08 因特格尔莫来库乐有限公司 包括双特异性型式的针对紧密连接蛋白6的抗体
CN120529914A (zh) 2023-01-09 2025-08-22 奥德赛治疗股份有限公司 抗tnfr2抗原结合蛋白及其用途
WO2024229370A1 (en) 2023-05-03 2024-11-07 Cartesian Therapeutics, Inc. Compositions and methods for treating gvhd
WO2024229350A1 (en) 2023-05-03 2024-11-07 Cartesian Therapeutics, Inc. Immunosuppressant in combination with high affinity il-2 receptor agonists for diabetes
WO2024229432A1 (en) 2023-05-03 2024-11-07 Cartesian Therapeutics, Inc. Synthetic nanocarriers comprising an immunosuppressant in combination with high affinity il-2 receptor agonists to enhance immune tolerance
WO2024229380A1 (en) 2023-05-03 2024-11-07 Cartesian Therapeutics, Inc. Immunosuppressant in combination with high affinity il-2 receptor agonists in autoimmune liver diseases
WO2025217240A1 (en) 2024-04-10 2025-10-16 Odyssey Therapeutics, Inc. Anti-tnfr2 antigen-binding proteins and uses thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008003473A2 (en) 2006-07-06 2008-01-10 Merck Patent Gmbh Compositions and methods for enhancing the efficacy of il-2 mediated immune responses
WO2012107417A1 (en) 2011-02-10 2012-08-16 Roche Glycart Ag Mutant interleukin-2 polypeptides
WO2012146628A1 (en) 2011-04-29 2012-11-01 Roche Glycart Ag Novel immunoconjugates
WO2014153111A2 (en) 2013-03-14 2014-09-25 Amgen Inc. Interleukin-2 muteins for the expansion of t-regulatory cells
JP2017527272A (ja) 2014-07-21 2017-09-21 デリニア， インコーポレイテッド 自己免疫疾患を治療するために調節性ｔ細胞を選択的に活性化する分子

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6541610B1 (en) * 1989-09-05 2003-04-01 Immunex Corporation Fusion proteins comprising tumor necrosis factor receptor
US6955807B1 (en) 1998-05-15 2005-10-18 Bayer Pharmaceuticals Corporation IL-2 selective agonists and antagonists
DE60222914T2 (de) 2001-07-27 2008-07-24 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Systeme zur stellengerichteten in-vivo-mutagenese mit oligonukleotiden
EP2354791A1 (en) 2001-12-04 2011-08-10 Merck Patent GmbH Immunocytokines with modulated selectivity
ATE525395T1 (de) 2003-06-12 2011-10-15 Lilly Co Eli Fusions proteine von glp-1-analoga
ES2383328T3 (es) * 2003-07-25 2012-06-20 Amgen, Inc Métodos relacionados con LDCAM y CRTAM
CN1930300A (zh) * 2004-03-05 2007-03-14 希龙公司 预测患者治疗药物耐受性的体外试验系统
CA2557677A1 (en) * 2004-03-05 2005-10-06 Chiron Corporation In vitro test system for predicting patient tolerability of therapeutic agents
SI2066694T1 (sl) * 2006-09-29 2016-02-29 Oncomed Pharmaceuticals, Inc. Sestavki in postopki za diagnosticiranje in zdravljenje raka
US20110274650A1 (en) * 2009-01-21 2011-11-10 Amgen Inc. Compositions and methods of treating inflammatory and autoimmune diseases
AR075896A1 (es) * 2009-03-20 2011-05-04 Genentech Inc Anticuerpos anti-her (factor de crecimiento epidermico)
PL2542590T5 (pl) * 2010-03-05 2020-08-10 The Johns Hopkins University Kompozycje i sposoby dla ukierunkowanych immunomodulatorowych przeciwciał i białek fuzyjnych
CN102174111B (zh) * 2011-01-25 2013-01-09 江苏省弗泰生物科技有限公司 人白介素2-Fc融合蛋白及其用途
JP2014094898A (ja) * 2012-11-07 2014-05-22 Univ Of Tsukuba 炎症性腸疾患に関連する、ＣＤ３００ａ発現細胞の活性調節剤を含有する医薬品、ならびにＣＤ３００ａ遺伝子欠損マウスおよびＣＤ３００ａ発現細胞の活性調節剤の使用
US10544187B2 (en) * 2013-03-15 2020-01-28 Xencor, Inc. Targeting regulatory T cells with heterodimeric proteins
CN103193887B (zh) * 2013-04-03 2015-02-04 江苏众红生物工程创药研究院有限公司 一种重组猪白细胞介素2-Fc融合蛋白及其编码基因和表达方法
US20170204154A1 (en) * 2016-01-20 2017-07-20 Delinia, Inc. Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008003473A2 (en) 2006-07-06 2008-01-10 Merck Patent Gmbh Compositions and methods for enhancing the efficacy of il-2 mediated immune responses
WO2012107417A1 (en) 2011-02-10 2012-08-16 Roche Glycart Ag Mutant interleukin-2 polypeptides
WO2012146628A1 (en) 2011-04-29 2012-11-01 Roche Glycart Ag Novel immunoconjugates
WO2014153111A2 (en) 2013-03-14 2014-09-25 Amgen Inc. Interleukin-2 muteins for the expansion of t-regulatory cells
KR102418771B1 (ko) 2013-03-14 2022-07-08 암젠 인크 T 조절 세포의 증식을 위한 인터류킨-2 뮤테인
JP2017527272A (ja) 2014-07-21 2017-09-21 デリニア， インコーポレイテッド 自己免疫疾患を治療するために調節性ｔ細胞を選択的に活性化する分子
JP6768633B2 (ja) 2014-07-21 2020-10-14 デリニア， インコーポレイテッド 自己免疫疾患を治療するために調節性ｔ細胞を選択的に活性化する分子

Also Published As

Publication number Publication date
ES2763198T3 (es) 2020-05-27
RS59789B1 (sr) 2020-02-28
JP6768633B2 (ja) 2020-10-14
EA038361B1 (ru) 2021-08-13
PT3172227T (pt) 2019-12-06
AU2015292889B2 (en) 2020-02-27
AU2015292889A1 (en) 2016-01-28
AU2020203480A1 (en) 2020-06-18
SG10202010158TA (en) 2020-11-27
US20190375812A1 (en) 2019-12-12
CN106795213A (zh) 2017-05-31
IL250024A0 (en) 2017-03-30
PL3172227T3 (pl) 2020-04-30
IL250024B (en) 2020-11-30
IL289475B2 (en) 2023-10-01
WO2016014428A3 (en) 2016-03-24
EP3172227B1 (en) 2019-09-04
ZA201700344B (en) 2020-08-26
GB201615553D0 (en) 2016-10-26
IL289475B1 (en) 2023-06-01
JP2017527272A (ja) 2017-09-21
EP3587444A1 (en) 2020-01-01
HUE046065T2 (hu) 2020-01-28
EA201790213A1 (ru) 2017-06-30
LT3172227T (lt) 2020-02-10
IL289475A (en) 2022-02-01
US20170051029A1 (en) 2017-02-23
MX378790B (es) 2025-03-10
EA202190903A3 (ru) 2021-12-31
WO2016014428A2 (en) 2016-01-28
US20210047382A1 (en) 2021-02-18
EP3172227A2 (en) 2017-05-31
KR20170028938A (ko) 2017-03-14
JP2021006038A (ja) 2021-01-21
SG11201700514SA (en) 2017-02-27
US20170327555A1 (en) 2017-11-16
EP3172227B9 (en) 2020-01-08
IL278299B (en) 2022-02-01
AU2022204946A1 (en) 2022-07-28
US20170037102A1 (en) 2017-02-09
US20220112260A1 (en) 2022-04-14
MX2021000083A (es) 2021-03-25
EA202190903A2 (ru) 2021-07-30
EP3172227A4 (en) 2017-12-20
CA2954847A1 (en) 2016-01-28
SI3172227T1 (sl) 2020-02-28
CN106795213B (zh) 2021-12-07
MX2017000821A (es) 2017-08-18
DK3172227T3 (da) 2019-12-02
CN114133456A (zh) 2022-03-04
AU2015292889C1 (en) 2023-01-19
GB2538666A (en) 2016-11-23

Similar Documents

Publication Publication Date Title
KR102493543B1 (ko) 자가면역 질환의 치료를 위한 조절 t 세포를 선택적으로 활성화시키는 분자
US11535657B2 (en) Molecules that selectively activate regulatory T cells for the treatment of autoimmune diseases
EA041387B1 (ru) Молекулы, которые избирательно активируют регуляторные t-клетки для лечения аутоиммунных заболеваний

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20170120

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
AMND Amendment
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20200716

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20220720

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20220928

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20220720

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20220928

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20220920

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20200716

Comment text: Amendment to Specification, etc.

PX0701 Decision of registration after re-examination

Patent event date: 20221117

Comment text: Decision to Grant Registration

Patent event code: PX07013S01D

Patent event date: 20221102

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20220928

Comment text: Decision to Refuse Application

Patent event code: PX07011S01I

Patent event date: 20220920

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20200716

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

X701 Decision to grant (after re-examination)
GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20230126

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20230126

End annual number: 3

Start annual number: 1

PG1601 Publication of registration